Clinical trial
A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
NCT03607487 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- Lead sponsor
- Incyte Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 15, 2018
- Completion date
- August 13, 2019
- Enrollment
- 35 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.